Bristol Myers Squibb Reports Positive Data from Camzyos Trial

Bristol Myers Squibb announced positive data from the Phase 3 Scout-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The Scout-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos versus placebo. Additionally, Camzyos showed meaningful improvement over placebo in multiple secondary endpoints at 28 weeks, and similar safety findings were observed in the Camzyos and placebo groups. The data are being presented as a late-breaking clinical trial presentation at the American College of Cardiology's, ACC, Annual Scientific Session & Expo 2026, with simultaneous publication in The New England Journal of Medicine. Scout-HCM evaluated Camzyos compared to placebo in 44 patients aged 12 to less than 18 years old with symptomatic oHCM and New York Heart Association class II-III symptoms over a 28-week period. In addition to meeting the primary endpoint of reduction of Valsalva LVOT gradient, Camzyos showed meaningful improvements over placebo in LV obstruction, diastolic function, maximal left ventricular wall thickness, NYHA class, and mitral valve dysfunction at 28 weeks.